Aelis Farma
Biotech company conducting research and development on innovative signaling specific drugs.
Launch date
Employees
Market cap
CAD88.7m
Enterprise valuation
CAD64m (Public information from Sep 2024)
Share price
€5.3 AELIS.PA
Company register number 797707627
Bordeaux Nouvelle-Aquitaine (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 9.1m | 3.8m | 9.1m | 54.0m | 12.4m | - |
| % growth | - | - | (58 %) | 138 % | 497 % | (77 %) | - |
| EBITDA | (2.8m) | 3.3m | (8.4m) | (4.6m) | 40.4m | (1.2m) | (9.4m) |
| % EBITDA margin | - | 37 % | (221 %) | (51 %) | 75 % | (10 %) | - |
| Profit | (2.1m) | <1m | (14.3m) | (5.1m) | 34.8m | (3.7m) | (10.9m) |
| % profit margin | - | 6 % | (375 %) | (56 %) | 64 % | (30 %) | - |
| EV / revenue | - | - | 36.4x | 17.2x | 1.4x | 6.6x | - |
| EV / EBITDA | - | - | -16.4x | -33.8x | 1.9x | -66.7x | -8.3x |
| R&D budget | 3.4m | 6.9m | 13.8m | 16.2m | - | - | - |
| R&D % of revenue | - | 76 % | 362 % | 179 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€9.0m | Grant | ||
€11.0m | Early VC | ||
| N/A | €6.0m | Grant | |
* | N/A | €25.0m | IPO |
| Total Funding | CAD39.0m | ||
Related Content
Recent News about Aelis Farma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.